About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Liquid Crystal Technology To Be Recruited In The War Against Cancer

by Medindia Content Team on September 8, 2007 at 6:35 PM
Font : A-A+

Liquid Crystal Technology To Be Recruited  In The  War  Against Cancer

Kent State University, Summa Health System and IC-MedTech Inc. have partnered to yield an innovative liquid crystal technology which offers the promise of new drugs that may more effectively manage cancer and other diseases.

Dr. Chun-che Tsai, Kent State professor of chemistry; Dr. Jim Jamison, manager of Urology, Obstetrics and Gynecology Core Basic Research Laboratory for Summa Health System; and Mr. Tom Miller, president of IC-MedTech Inc., a California-based biotechnology company, have developed a new paradigm in drug discovery based on the pharmacologic properties of liquid crystals called Liquid Crystal Pharmaceuticals™ or LCPs.

Advertisement

Recently, the team gathered at Kent State University's Office of Technology Transfer to file applications for two new patents: one for a new LCP-based anti-tumor drug called Tolecine™ and another for a formulation that combines Tolecine™ and another LCP, Apatone®.

"The path-breaking discoveries of Dr. Tsai and his colleagues offer compelling proof of the value of university research and the enormous good that can come from collaborations between universities and the private sector," says Kent State President Lester A. Lefton. "As Kent State researchers tackle cancer and a host of other real-world ills and issues, they are bringing their leading-edge knowledge and creativity to our students and playing a significant role in economic development."
Advertisement

Though best known for their use in laptops, televisions and cell phones, liquid crystals also include families of organic substances that are essential for all life called lyotropic liquid crystals. Examples of lyotropic liquid crystals include DNA, proteins and cholesterol. LCPs are a unique class of lyotropic liquid crystals that represent novel drug candidates for the treatment of a wide range of diseases.

"Mother nature is the ultimate chemist," says Tsai. "Although we use creative and sophisticated computer modeling techniques to screen for our candidate compounds, I'm always amazed at how nature puts it all together."

The most recent research involving LCPs has yielded a new investigational anti-tumor drug called Tolecine™, a compound that also has antiviral and antibacterial applications. Created by Tsai, it has been shown to be even more effective than the current standard of care for herpes.

The team's second patent application involves a formulation that combines Tolecine™ and another LCP, Apatone®, which attacks cancer cells via multiple pathways to offer improved efficacy. Apatone® has been successfully tested in more than 30 human tumor cell lines at Summa and in a Phase I/IIa clinical trial, which demonstrated a delaying effect in the progression of end-stage cancer patients. In addition, the FDA granted Apatone® orphan-drug status for the treatment of metastatic, or locally advanced, inoperable bladder cancer in August 2007.

Unlike other chemotherapy drugs, TolecineTM and Apatone®have low toxicity and do not target dividing cells. Instead, they are activated by inflammation that occurs in and around tumor cells, sparing healthy cells. "We want to kill cancer cells specifically without killing surrounding tissues," says Jamison.

Innovative, low-toxicity drugs such as Tolecine™ and Apatone®provide new hope in the battle against cancer and other diseases in the next few years. "Research on LCPs provides a solid scientific foundation for generations of new drugs," says Miller. Adds Tsai: "LCPs are an untapped frontier from which many new, exciting treatments are now emerging."

Source: Eurekalert
LIN /J
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Iodine Deficiency Disorder Cancer and Homeopathy Cancer Facts Cancer Colors and Moods 

Recommended Reading
Brain Tumor
Brain tumors are the abnormal growth of brain cells that may be benign or metastatic. Brain tumors ....
FDA’s Genetic Screening for Cancer Drug Needless
Researchers at the University of North Carolina have questioned the FDA's need for genetic ......
Colors and Moods
Study of the psychology of color, technically termed as chromology delves into the influence of colo...
Iodine Deficiency Disorder
To control IDD, the ‘National Goiter Control Program (NGCP)’ was launched which was later renamed as...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use